| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3120ae9cab5bb4831f0cc16288966367 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2011-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de09bf167d16a691f63d26a992d0261b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d724031ef02623f99ff0d0804598b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0a8c96d6099407decd1d9731c21c3aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31294dbc6eb3547f3f4072030d833468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4eafd0964df0a8ecae38cec1cc650f77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9b8cc2608bc3acb2b2b87c10158846a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07aa4c8cdfd7fcfb91115a6110a092f3 |
| publicationDate |
2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011121963-A |
| titleOfInvention |
Insulin composition and method for producing the composition |
| abstract |
The present invention provides a pharmaceutical composition of acylated insulin having a prolonged action characteristic and a high zinc content. An insulin composition having a high zinc atom content for every six molecules of acylated insulin, wherein the insulin is an acylated insulin. It may be an acylated insulin dodecamer complex or a complex having a higher molecular weight than the acylated insulin dodecamer. It may be mixed with further insulin analogues such as, for example, fast acting insulin AspB28 human insulin. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020502145-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10596231-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020105227-A |
| priorityDate |
2005-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |